[go: up one dir, main page]

NO20090908L - Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav - Google Patents

Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav

Info

Publication number
NO20090908L
NO20090908L NO20090908A NO20090908A NO20090908L NO 20090908 L NO20090908 L NO 20090908L NO 20090908 A NO20090908 A NO 20090908A NO 20090908 A NO20090908 A NO 20090908A NO 20090908 L NO20090908 L NO 20090908L
Authority
NO
Norway
Prior art keywords
disease
pharmaceutically acceptable
relates
methods
variety
Prior art date
Application number
NO20090908A
Other languages
English (en)
Norwegian (no)
Inventor
William W Bachovchin
Hung-Sen Lai
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of NO20090908L publication Critical patent/NO20090908L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20090908A 2006-08-03 2009-02-27 Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav NO20090908L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83519406P 2006-08-03 2006-08-03
PCT/US2007/074960 WO2008016968A2 (fr) 2006-08-03 2007-08-01 Analogues de la niacine sans effets de bouffées congestives et procédés d'utilisation

Publications (1)

Publication Number Publication Date
NO20090908L true NO20090908L (no) 2009-05-04

Family

ID=38997834

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090908A NO20090908L (no) 2006-08-03 2009-02-27 Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav

Country Status (12)

Country Link
US (4) US8377971B2 (fr)
EP (1) EP2054386B1 (fr)
JP (1) JP5270545B2 (fr)
KR (1) KR101403887B1 (fr)
CN (1) CN101522623B (fr)
AU (1) AU2007281212B8 (fr)
BR (1) BRPI0714793A2 (fr)
CA (1) CA2659747C (fr)
IL (1) IL196763A (fr)
MX (1) MX2009001279A (fr)
NO (1) NO20090908L (fr)
WO (1) WO2008016968A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016968A2 (fr) * 2006-08-03 2008-02-07 Trustees Of Tufts College Analogues de la niacine sans effets de bouffées congestives et procédés d'utilisation
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
US8937063B2 (en) 2010-06-24 2015-01-20 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CA2861643C (fr) 2012-01-06 2020-10-06 Charles L. Bisgaier Methodes de reduction du risque de maladie cardiovasculaire
MX378998B (es) 2015-06-03 2025-03-11 Bristol Myers Squibb Co Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
JP2018536710A (ja) 2015-11-06 2018-12-13 ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 混合型脂質異常症の治療
CA3093445A1 (fr) 2018-03-08 2019-11-28 Incyte Corporation Composes d'aminopyrazine diol utilises comme inhibiteurs de pi3k-.gamma.
CN111918670A (zh) * 2018-03-13 2020-11-10 努其杜有限公司 组合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
EP0013153B1 (fr) * 1978-12-27 1982-12-22 Beecham Group Plc Dérivés d'acides 6-aminopyridine carboxyliques, procédé pour leur préparation, et compositions pharmaceutiques les contenant
CA1155842A (fr) * 1980-03-29 1983-10-25 Thomas H. Brown Composes
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5352684A (en) 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
EP1114048A1 (fr) * 1998-09-16 2001-07-11 Agnès Bombrun Derives de carboline en tant qu'inhibiteurs de la gmp cyclique phosphodiesterase
CA2456096A1 (fr) 2001-08-01 2003-02-13 Mochida Pharmaceutical Co., Ltd. Nouveau derive amine presentant une activite inhibant la (.beta.)-tryptase humaine et medicaments contenant ce nouveau derive
WO2003028724A1 (fr) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Inhibiteurs de la kinase chk1
TW200418835A (en) * 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
EP1761496A2 (fr) * 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Heterocycles ne comprenant pas d`imidazole utilisables comme ligands des recepteurs histamine h3
CN1980665A (zh) * 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
JP2006056884A (ja) 2004-07-23 2006-03-02 Tanabe Seiyaku Co Ltd 医薬組成物
CN101056635A (zh) * 2004-11-04 2007-10-17 默克公司 烟酸受体激动剂、含有该化合物的组合物及治疗方法
JP2008520715A (ja) * 2004-11-23 2008-06-19 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、そのような化合物を含む組成物、および治療方法
EP1885697A2 (fr) * 2005-05-06 2008-02-13 Boehringer Ingelheim International Gmbh Inhibiteurs de l'epoxyde hydrolase soluble et leurs methodes d'utilisation
NZ563866A (en) * 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
DE102005062379A1 (de) 2005-12-23 2007-06-28 Basf Ag Carbamatgruppenhaltiger Co-Vernetzer
JP2009544616A (ja) 2006-07-21 2009-12-17 武田薬品工業株式会社 アミド化合物
WO2008016968A2 (fr) * 2006-08-03 2008-02-07 Trustees Of Tufts College Analogues de la niacine sans effets de bouffées congestives et procédés d'utilisation

Also Published As

Publication number Publication date
WO2008016968A3 (fr) 2008-12-18
US8889720B2 (en) 2014-11-18
AU2007281212B2 (en) 2012-11-01
US20090312355A1 (en) 2009-12-17
JP5270545B2 (ja) 2013-08-21
US9193708B2 (en) 2015-11-24
CA2659747C (fr) 2015-09-08
JP2009545616A (ja) 2009-12-24
AU2007281212A1 (en) 2008-02-07
IL196763A0 (en) 2009-11-18
KR101403887B1 (ko) 2014-06-20
CN101522623B (zh) 2013-06-12
MX2009001279A (es) 2009-02-11
EP2054386B1 (fr) 2014-10-08
US9511060B2 (en) 2016-12-06
IL196763A (en) 2014-05-28
US8377971B2 (en) 2013-02-19
CA2659747A1 (fr) 2008-02-07
EP2054386A2 (fr) 2009-05-06
BRPI0714793A2 (pt) 2015-06-16
KR20090035034A (ko) 2009-04-08
AU2007281212B8 (en) 2013-02-28
WO2008016968A2 (fr) 2008-02-07
EP2054386A4 (fr) 2010-03-17
CN101522623A (zh) 2009-09-02
US20150099787A1 (en) 2015-04-09
US20160151343A1 (en) 2016-06-02
AU2007281212A8 (en) 2013-02-28
US20130217714A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
NO20090908L (no) Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav
JP2008521829A5 (fr)
JP2008521831A5 (fr)
FI4157832T3 (fi) Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
WO2010036613A8 (fr) Nouveaux dérivés de benzimidazole cycliques utiles en tant qu'agents anti-diabétiques
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
MA32368B1 (fr) Derives d'acide cyclopentanecarboxylique condensé acylamino-substitues et leur utilisation en tant qu'agents pharmaceutiques
JP2017509624A5 (fr)
BR112017017189A2 (pt) mistura de ácidos carboxílicos para o tratamento de pacientes com insuficiência renal
TWI256890B (en) Hetero biaryl derivatives as matrix metalloproteinase inhibitors
CY1114857T1 (el) Τροποποιημενα ενζυμα λεκιθινο-χοληστερολικης ακυλοτρανσφερασης
Ferraris et al. δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors
JP2016521279A5 (fr)
EA200870433A1 (ru) Азагетероциклильные производные андростанов и андростенов в качестве лекарственных средств от сердечно-сосудистых расстройств
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
NO20080457L (no) Kjemiske forbindelser
Okumura et al. Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist
WO2008043024A3 (fr) Formulation pharmaceutique orale comprenant un sulfonyle bicyclique modulateur de ppar pour le traitement d'une maladie
EA201270248A1 (ru) Азетидиноновые соединения и медицинское применение указанных соединений
Kant et al. Small Molecule Assembly Agonist Alters the Dynamics of Hepatitis B Virus Core Protein Dimer and Capsid
DK1750703T3 (da) Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur
Ahn et al. Clinical outcomes according to the achievement of target low density lipoprotein-cholesterol in patients with acute myocardial infarction
WO2024155965A3 (fr) Biomarqueurs destinés à être utilisés en thérapie par inhibiteur d'intégrine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application